In past few years, immunotherapy has gained a lot of popularity in global cancer therapeutics market owing to its targeted nature and high efficacy. Among all immunotherapeutic approaches, therapeutic antibodies have gained maximum attention to scientists owing to their small size, high efficacy and specificity towards the cancer cells. To date, a cocktail of therapeutic antibodies including monoclonal and bispecific antibodies have entered the market which have shown robust response in the market.
Although 2 bispecific antibodies have been introduced for the management of cancer, but the top selling antibodies consists only monoclonal antibodies. This is mainly due to less awareness about the availability of bispecific antibodies among patients. In addition, the monoclonal antibodies have been approved for several oncological conditions while the bispecific antibodies are only approved for few. However, the pipeline of bispecific antibody is highly crowded and they are expected to flourish the market in coming years.,/p>
The increase in incidence of cancer across globe is one of the key factors driving the growth of market. In comparison to traditionally used non-targeted therapies, therapeutic antibodies have shown lesser side effects, which will further propel the growth of market. The major pharmaceutical companies working in global cancer antibody market includes Amgen, Roche, Pfizer, Novartis, Eli Lilly, Bristol Meyer Squibb, GlaxoSmithKline, and others.
| Drug | Company | Approved | Indication | 2021 Sales |
| Keytruda | Merck | 2014 | melanoma, NSCLC, HNSCC, classical HL, primary mediastinal large B-cell lymphoma, urothelial carcinoma, CRC, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma, and TNBC. | US$ 17.18 Billion |
| Opdivo | Bristo Myers Squibb | 2014 | NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, HNSCC, urothelial carcinoma, CRC, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer. | US$ 7.52 Billion |
| Tecentriq | Genentech | 2016 | Bladder Cancer, NSCLC, Breast Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma | US$ 3.58 Billion |
| Avastin | Genentech | 2004 | Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Hepatocellular Carcinoma | US$ 3.3 Billion |
| Herceptin | Genentech | 1998 | Breast Cancer, Gastric Cancer | US$ 2.91 Billion |
| Rituximab | Genentech | 1997 | Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Non-Hodgkin’s Lymphoma, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Pemphigus | US$ 2.77 Billion |
| Yervoy | Bristol Myers Squibb | 2011 | Melanoma, Metastatic, Renal Cell Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma | US$ 2.02 Billion |
| Darzalex | Janssen Biotech | 2015 | Multiple Myeloma | US$ 1.64 Billion |
| Xgeva | Amgen | 2010 | Osteolytic Bone Metastases of Solid Tumors, Osteolytic Bone Lesions of Multiple Myeloma, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy | US$ 1.43 Billion |
| Vectibix | Amgen | 2006 | Colorectal Cancer | US$ 873 Million |
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Insight Till Dec 2021(Updated Every Quarter)
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
Download Report:
Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- LAG-3 Targeted Approach in Cancer Therapy
- Therapeutic Approaches for Novel LAG-3 Targeted Therapy
- Global LAG 3 Inhibitor Market Future Outlook
Download Report:
US Cancer Antibody Market, Drug Price, Sales and Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- US Cancer Antibody Market Analysis Till 2026
- US Cancer Antibodies Market Size Opportunity by Therapeutic Class
- Insight on FDA Approved 57 Cancer Antibodies Available in US Market
- Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market
- Key Market Dynamics
- Competitor Landscape
Download Report:
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366